US likely to allow Poolbeg application to expand intellectual property protection

Poolbeg Pharma said on Tuesday that the US Patent and Trademarks Office has indicated that it is likely to accept the company’s application to expand its intellectual property protections around its lead asset, a drug called POLB 001.

Mostly aimed at treating severe influenza, the clinical late-stage pharmaceutical company – which spun out from Open Orphan in 2021 – received UK regulatory approval in July to proceed with human clinical trials of the drug.

While London-listed Poolbeg already holds European and US patents for the drug for the treatment of flu, POLB 001 has other potential uses, including the treatment of hypercytokinemia.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

Poolbeg Pharma strategic expansion of POLB 001 into oncology

Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced the strategic expansion of POLB 001 into oncology. While investigating the role of cytokine release syndrome in severe influenza, Poolbeg discovered data specific to the overt immune

Licensing deal could pave way for new treatments for metabolic diseases

In a proof-of-concept clinical trial, Poolbeg Pharma will look into the potential of microencapsulation and nanoencapsulation oral delivery technologies. Poolbeg Pharma has acquired a licence from a sister company of Cork start-up AnaBio Technologies for an innovative treatment

Year in review 2022

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma clinical trials for viral strain agnostic

Poolbeg Pharma received initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza.  Key highlights from

Poolbeg Pharma identifies new potential drug candidates for RSV infections

Poolbeg Pharma has identified new potential drug candidates for respiratory syncytial virus (RSV) infections. The identification of potential RSV treatments has emerged from the company’s artificial intelligence (AI) programme alongside partner OneThree Biotech. The collaboration between the two

Poolbeg Pharma identifies potential new drug candidates from its RSV AI programme

Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus artificial intelligence Programme with OneThree Biotech, Inc. Since initiating the collaboration in February 2022,

Poolbeg Pharma acquires exclusive licence from InsuCaps

Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced that it has acquired an exclusive licence from InsuCaps Limited, a sister company of AnaBio Technologies, to use InsuCaps’ patented microencapsulation and nanoencapsulation oral delivery technologies

Introduction to David English, VP of Business Development

VP of Business Development at Poolbeg Pharma, David English, gives an overview of his experience and why he decided to join the Poolbeg Pharma team. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with

Poolbeg Pharma influenza AI model completed by CytoReason

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that, further to its announcement in March 2022, the construction of the computational artificial intelligence (AI) influenza disease model has been completed by

No more posts to show